SALT LAKE CITY, UTAH, USA, February 14, 2018 /EINPresswire.com/ — Leaders at Intermountain Precision Genomics are pleased to announce the Utah based genomics program has been featured in a Harvard Business School case study published by Harvard Business Review. The case study, “Intermountain Healthcare: Pursuing Precision Medicine” chronicles the four-year journey of Intermountain’s precision medicine program in its goal to provide cutting-edge care for cancer patients.
Presentation of the twenty-two page case study to Harvard MBA students at the Harvard Business School initially occurred in October 2017. The Precision Medicine Coalition hosted a precision medicine conference in November at Harvard Medical School where the case was presented to medical professionals in attendance. Subsequent discussion forums will continue to take place.
According to Lincoln Nadauld, MD, Ph. D., Executive Director of Intermountain Precision Genomics and Precision Medicine, “Historically, many healthcare innovations have arisen in large academic institutions. Intermountain Precision Genomics is an example of implementing medical discovery within a large integrated health network as opposed to a large academic medical center.” Nadauld adds, “Students and healthcare providers can learn from the successes and challenges associated with healthcare innovation. They can also debate the merits of healthcare systems trying to implement practice changing clinical programs. This case is significant because it is an example of the clinical implementation of precision medicine and how it can positively impact patients. It is also an example of how a large hospital system can embrace and enable healthcare innovation.”
Intermountain Healthcare is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. Intermountain Precision Genomics (IPG) is a service of Intermountain Healthcare. For more information about Intermountain Precision Genomics, please visit: precisioncancer.org, join the dialog on Facebook (Intermountain Cancer Centers) or follow @intermtncancer on Twitter.
email us here
Source: EIN Presswire